Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-07-25 , DOI: 10.1016/s1470-2045(24)00313-9
Xin Liu ₁ , Xiaowei Zhang ₁ , Shiyu Jiang ₁ , Miao Mo ₂ , Qifeng Wang ₃ , Yanli Wang ₃ , Liangping Zhou ₄ , Silong Hu ₅ , Huijuan Yang ₆ , Yifeng Hou ₇ , Yong Chen ₈ , Xueguan Lu ₉ , Yu Wang ₁₀ , Xiaoyan Zhou ₃ , Wentao Li ₁₁ , Cai Chang ₁₂ , Xiujiang Yang ₁₃ , Ke Chen ₁₃ , Jun Cao ₁ , Qinghua Xu ₁₄ , Yifeng Sun ₁₅ , Jianfeng Luo ₁₆ , Zhiguo Luo ₁ , Xichun Hu ₁

Affiliation

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Head & Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
The Canhelp Genomics Research Center, Canhelp Genomics, Hangzhou, China.
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; The Canhelp Genomics Research Center, Canhelp Genomics, Hangzhou, China; Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.

Empirical chemotherapy remains the standard of care in patients with unfavourable cancer of unknown primary (CUP). Gene-expression profiling assays have been developed to identify the tissue of origin in patients with CUP; however, their clinical benefit has not yet been demonstrated. We aimed to evaluate the efficacy and safety of site-specific therapy directed by a 90-gene expression assay compared with empirical chemotherapy in patients with CUP.

中文翻译：

原发性不明癌症患者由 90 基因表达测定指导的部位特异性治疗与经验性化疗（Fudan CUP-001）：一项随机对照试验

经验性化疗仍然是原发性不明癌症（CUP）患者的标准治疗。已经开发了基因表达谱分析测定法来识别 CUP 患者的组织来源;然而，它们的临床益处尚未得到证实。我们旨在评估 90 基因表达测定指导的部位特异性治疗与 CUP 患者经验性化疗相比的疗效和安全性。

更新日期：2024-07-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文